VYNE Therapeutics (VYNE) EBIAT (2016 - 2025)
VYNE Therapeutics' EBIAT history spans 10 years, with the latest figure at -$5.8 million for Q2 2025.
- For Q2 2025, EBIAT rose 38.74% year-over-year to -$5.8 million; the TTM value through Jun 2025 reached -$38.5 million, down 38.24%, while the annual FY2025 figure was -$26.7 million, 32.84% up from the prior year.
- EBIAT reached -$5.8 million in Q2 2025 per VYNE's latest filing, up from -$8.6 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $17.6 million in Q4 2021 to a low of -$21.3 million in Q3 2021.
- Average EBIAT over 5 years is -$7.6 million, with a median of -$8.4 million recorded in 2022.
- Peak YoY movement for EBIAT: skyrocketed 175.71% in 2021, then plummeted 220.39% in 2023.
- A 5-year view of EBIAT shows it stood at $17.6 million in 2021, then tumbled by 144.22% to -$7.8 million in 2022, then rose by 20.73% to -$6.2 million in 2023, then tumbled by 95.17% to -$12.0 million in 2024, then surged by 52.07% to -$5.8 million in 2025.
- Per Business Quant, the three most recent readings for VYNE's EBIAT are -$5.8 million (Q2 2025), -$8.6 million (Q1 2025), and -$12.0 million (Q4 2024).